MTORC1 protein inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “MTORC1 Protein Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in MTORC1 Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Overview
mTOR is a serine/threonine protein kinase in the PI3K-related kinase (PIKK) family that forms the catalytic subunit of two distinct protein complexes, known as mTOR Complex 1 (mTORC1) and 2 (mTORC2). mTORC1 is defined by its three core components: mTOR, Raptor (regulatory protein associated with mTOR), and mLST8 (mammalian lethal with Sec13 protein 8, also known as G?L).
Function - In order to grow and divide, cells must increase production of proteins, lipids, and nucleotides while also suppressing catabolic pathways such as autophagy. mTORC1 plays a central role in regulating all of these processes, and therefore controls the balance between anabolism and catabolism in response to environmental conditions. mTORC1 promotes protein synthesis largely through the phosphorylation of two key effectors, p70S6 Kinase 1 (S6K1) and eIF4E Binding Protein (4EBP). mTORC1 directly phosphorylates S6K1 on its hydrophobic motif site, Thr389, enabling its subsequent phosphorylation and activation by PDK1.
MTORC1 Protein Inhibitors - New mTOR-specific inhibitors came forth from screening and drug discovery efforts. These compounds block activity of both mTOR complexes and are called mTORC1/mTORC2 dual inhibitors. Compounds with this characteristics such as sapanisertib have entered clinical trials. A series of these mTOR kinase inhibitors have been studied. Their structure is derived from morpholino pyrazolopyrimidine scaffold. Improvements of this type of inhibitors have been made by exchanging the morpholines with bridged morpholines in pyrazolopyrimidine inhibitors and results showed increased selectivity to mTOR by 26000 fold.
MTORC1 Protein Inhibitors Emerging Drugs Chapters
This segment of the MTORC1 Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MTORC1 Protein Inhibitors Emerging Drugs
Further product details are provided in the report……..
MTORC1 Protein Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different MTORC1 Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
MTORC1 Protein Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses MTORC1 Protein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MTORC1 Protein Inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “MTORC1 Protein Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in MTORC1 Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Overview
mTOR is a serine/threonine protein kinase in the PI3K-related kinase (PIKK) family that forms the catalytic subunit of two distinct protein complexes, known as mTOR Complex 1 (mTORC1) and 2 (mTORC2). mTORC1 is defined by its three core components: mTOR, Raptor (regulatory protein associated with mTOR), and mLST8 (mammalian lethal with Sec13 protein 8, also known as G?L).
Function - In order to grow and divide, cells must increase production of proteins, lipids, and nucleotides while also suppressing catabolic pathways such as autophagy. mTORC1 plays a central role in regulating all of these processes, and therefore controls the balance between anabolism and catabolism in response to environmental conditions. mTORC1 promotes protein synthesis largely through the phosphorylation of two key effectors, p70S6 Kinase 1 (S6K1) and eIF4E Binding Protein (4EBP). mTORC1 directly phosphorylates S6K1 on its hydrophobic motif site, Thr389, enabling its subsequent phosphorylation and activation by PDK1.
MTORC1 Protein Inhibitors - New mTOR-specific inhibitors came forth from screening and drug discovery efforts. These compounds block activity of both mTOR complexes and are called mTORC1/mTORC2 dual inhibitors. Compounds with this characteristics such as sapanisertib have entered clinical trials. A series of these mTOR kinase inhibitors have been studied. Their structure is derived from morpholino pyrazolopyrimidine scaffold. Improvements of this type of inhibitors have been made by exchanging the morpholines with bridged morpholines in pyrazolopyrimidine inhibitors and results showed increased selectivity to mTOR by 26000 fold.
MTORC1 Protein Inhibitors Emerging Drugs Chapters
This segment of the MTORC1 Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MTORC1 Protein Inhibitors Emerging Drugs
- Onatasertib (CC 223): Celgene
- Sapanisertib :Takeda Oncology
Further product details are provided in the report……..
MTORC1 Protein Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different MTORC1 Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on MTORC1 Protein Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
MTORC1 Protein Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses MTORC1 Protein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MTORC1 Protein Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence MTORC1 Protein Inhibitors R&D. The therapies under development are focused on novel approaches for MTORC1 Protein Inhibitors.
- MTORC1 Protein Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing MTORC1 Protein Inhibitors drugs?
- How many MTORC1 Protein Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for MTORC1 Protein Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the MTORC1 Protein Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for MTORC1 Protein Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Celgene
- Takeda Oncology
- Mount Tam Biotechnologies
- Cerecor
- Adicet Bio
- Aeonian Pharmaceuticals
- Boehringer Ingelheim
- REVOLUTION Medicines
- Sotorasib
- Sapanisertib
- Research programme: mTOR inhibitors
- CERC 006
- mTORC1 inhibitor programme II
- XP 105
- RMC-5552
Introduction
Executive Summary
MTORC1 Protein Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
MTORC1 Protein Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
MTORC1 Protein Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
MTORC1 Protein Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Onatasertib (CC 223): Celgene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CERC 006: Cerecor
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Research programme: mTOR inhibitors: Mount Tam Biotechnologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
MTORC1 Protein Inhibitors Key Companies
MTORC1 Protein Inhibitors Key Products
MTORC1 Protein Inhibitors- Unmet Needs
MTORC1 Protein Inhibitors- Market Drivers and Barriers
MTORC1 Protein Inhibitors- Future Perspectives and Conclusion
MTORC1 Protein Inhibitors Analyst Views
MTORC1 Protein Inhibitors Key Companies
Appendix
Executive Summary
MTORC1 Protein Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
MTORC1 Protein Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
MTORC1 Protein Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
MTORC1 Protein Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Onatasertib (CC 223): Celgene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CERC 006: Cerecor
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Research programme: mTOR inhibitors: Mount Tam Biotechnologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
MTORC1 Protein Inhibitors Key Companies
MTORC1 Protein Inhibitors Key Products
MTORC1 Protein Inhibitors- Unmet Needs
MTORC1 Protein Inhibitors- Market Drivers and Barriers
MTORC1 Protein Inhibitors- Future Perspectives and Conclusion
MTORC1 Protein Inhibitors Analyst Views
MTORC1 Protein Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for MTORC1 Protein Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for MTORC1 Protein Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for MTORC1 Protein Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for MTORC1 Protein Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
